Sabrina Serani

Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.

Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.

How a community center launches CAR T and bispecific care: managing CRS/ICANS outpatient, closing access gaps, adapting to REMS.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and pan-cancer testing implications.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting pain post thoracotomy and reducing opioid use.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

Ryan Funk, MD, explains how 2026 CMS coding changes and commercial payer contracts are straining radiation oncology practices, threatening rural and freestanding centers and patient access to care.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.

A gynecologic oncologist unpacks shifting cancer trends, HRD and germline testing, screening pitfalls, and where new treatments are headed.

A guide to breast cancer biomarker testing, from ER/PR and HER2-low status to PIK3CA, AKT1, and ESR1 mutations across diagnosis and disease progression.

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

A guide to the biomarkers oncologists should test for in NSCLC, from established drivers like EGFR and ALK to newer targets such as MET exon 14 and HER2.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.

Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.

Javier Cortés, MD, PhD, discusses the final KEYNOTE-522 analysis, showing pembrolizumab plus chemotherapy sustains long-term survival benefit in early-stage TNBC.

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Erika Hamilton, MD, discusses HER2CLIMB-05 data showing tucatinib plus HP maintenance extends PFS in HER2+ breast cancer, including brain metastases.

Erica Stringer-Reasor, MD, of UAB, discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

Experts weigh newer ROS1 inhibitors like taletrectinib, highlighting long responses, fewer CNS/GI side effects, and trial challenges in rare NSCLC.

Phase 1 TRAVERSE results show that off-the-shelf CD70 CAR T ALLO-316 drives durable responses in refractory clear cell kidney cancer, with manageable safety signals.

Phase 2 KEYPAD shows pembrolizumab plus denosumab yields 31% responses and 7.5-month PFS in VEGFR-TKI–pretreated clear-cell RCC.